AF
BEAM icon

Amalgamated Financial’s Beam Therapeutics BEAM Stock Holding History

Amalgamated Financial’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$480K Buy
+8,379
New +$550K ﹤0.01% 1527

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's BEAM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Beam Therapeutics (BEAM) in Q1 2022: 8,379 shares worth $480K. The stake represents ﹤0.01% of the portfolio and ranks #1527 among its holdings.

240 funds tracked by Wall St. Rank hold BEAM as of Q1 2022.

  • Amalgamated Financial held 8,379 shares of Beam Therapeutics worth $480K as of Q1 2022.
  • Beam Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Beam Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1527 holding.
  • 240 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.